NeuroPace (NPCE) Cash from Operations Growth (3y) (2023 - 2026)
NeuroPace (NPCE) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.80 Bn | 176.50 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.84 Bn | 125.96 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 108.59 Bn | 99.37 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.51 Bn | 67.06 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 48.18 Bn | 44.51 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 28.40 Bn | 27.28 Bn | 750.30 Mn | 50.11% |
| 7 | GE HealthCare Technologies | 28.16 Bn | 25.88 Bn | 1.98 Bn | -14.75% |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 24.66 Bn | 21.54 Bn | 2.07 Bn | 0.50% |
| 10 | NeuroPace | 515.87 Mn | 461.89 Mn | 18.05 Mn | 15.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.27% |
| Dec 31, 2025 | 27.31% |
| Sep 30, 2025 | 34.66% |
| Jun 30, 2025 | 42.18% |
| Mar 31, 2025 | 13.03% |
| Dec 31, 2024 | 16.94% |
| Sep 30, 2024 | 26.29% |
| Jun 30, 2024 | 13.41% |
| Mar 31, 2024 | -8.33% |
| Dec 31, 2023 | 19.85% |
| Sep 30, 2023 | 24.76% |
| Jun 30, 2023 | -10.08% |
| Mar 31, 2023 | -14.27% |